Outlook Therapeutics is trading at $0.50, down -10.82%, with broader market and biotech weakness a plausible contributor.
- No company-specific announcement dated October 14 explains the drop; the latest listed release, October 9, named a chief commercial officer.
- September CPI ran hotter than forecast, while market context showed major indexes lower and biotech weak.
- The decline substantially outpaced the cited sector and index moves; no specific explanation for the additional weakness was identified.